We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+7.32%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$130M
(-7.3%)
Cap. Flow
-$202M
Cap. Flow
% of AUM
-12.26%
Top 10 Holdings %
Top 10 Hldgs %
56.48%
Holding
64
New
19
Increased
12
Reduced
10
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$98.3M |
| 2 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$93.8M |
| 3 |
Zimmer Biomet
ZBH
|
+$90.7M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$61.2M |
| 5 |
DexCom
DXCM
|
+$60.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$129M |
| 2 |
Edwards Lifesciences
EW
|
+$113M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$108M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$82.1M |
| 5 |
AET
Aetna Inc
AET
|
+$71.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.96% |
| 2 | Financials | 0% |
| 3 | Industrials | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCR
1
DELISTED
CR Bard Inc.
BCR
| $133M | 8.05% |
700,000
+150,000
| +27% | +$28.1M |
|
2
Eli Lilly
LLY
$1.03T
| $112M | 6.78% |
1,325,000
+325,000
| +33% | +$27M |
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $111M | 6.75% |
2,300,000
+400,000
| +21% | +$17.3M |
|
|
BXLT
4
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $105M | 6.38% |
+2,690,440
| New | +$93.8M |
|
5
Labcorp
LH
$25.9B
| $98.9M | 6.01% |
931,200
+291,000
| +45% | +$30M |
|
|
6
Zimmer Biomet
ZBH
$18.4B
| $92.3M | 5.61% |
+927,000
| New | +$90.7M |
|
|
AKRX
7
DELISTED
Akorn Inc
AKRX
| $74.6M | 4.53% |
2,000,000
-325,000
| -14% | -$10.2M |
|
8
Abbott
ABT
$183B
| $74.5M | 4.52% |
1,658,540
-591,460
| -26% | -$26.1M |
|
|
9
Teva Pharmaceuticals
TEVA
$41.2B
| $65M | 3.95% |
+990,510
| New | +$61.2M |
|
|
CVRS
10
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $64.1M | 3.9% |
19,981,655
| – | – |
|
|
11
DexCom
DXCM
$28.8B
| $61.4M | 3.73% |
3,000,000
+2,900,000
| +2,900% | +$60.3M |
|
12
Vertex Pharmaceuticals
VRTX
$122B
| $59.4M | 3.61% |
471,970
-178,030
| -27% | -$21.5M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $53.4M | 3.24% |
+1,525,000
| New | +$98.3M |
|
14
Pfizer
PFE
$142B
| $50.7M | 3.08% |
1,654,917
-1,164,533
| -41% | -$36.6M |
|
15
Viatris
VTRS
$20.7B
| $48.7M | 2.96% |
+901,510
| New | +$43.4M |
|
16
Cencora
COR
$60.7B
| $47.6M | 2.89% |
+459,140
| New | +$45.1M |
|
17
Brookdale Senior Living
BKD
$3.49B
| $46.1M | 2.8% |
2,500,000
+575,000
| +30% | +$12.4M |
|
18
Universal Health Services
UHS
$9.88B
| $43.8M | 2.66% |
366,390
-108,610
| -23% | -$13.3M |
|
19
Quest Diagnostics
DGX
$25.9B
| $37.3M | 2.27% |
+524,650
| New | +$35.3M |
|
20
Incyte
INCY
$24.9B
| $34.9M | 2.12% |
+322,030
| New | +$35.9M |
|
21
Icon
ICLR
$12.8B
| $31.1M | 1.89% |
+400,000
| New | +$28.6M |
|
22
Collegium Pharmaceutical
COLL
$1.17B
| $28.2M | 1.71% |
1,025,000
+75,000
| +8% | +$1.58M |
|
|
SGNT
23
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $27.8M | 1.69% |
1,750,000
+500,000
| +40% | +$7.87M |
|
24
Acadia Pharmaceuticals
ACAD
$4.55B
| $20.9M | 1.27% |
586,564
-92,136
| -14% | -$3.25M |
|
|
MNK
25
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $18.6M | 1.13% |
+249,390
| New | +$16.8M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2015 Portfolio in Review
As of Q4 2015, HealthCor Management held 64 positions worth $1.65B, down 7.3% from $1.78B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
HealthCor Management withdrew a net $202M in Q4 2015, closing 22 positions and reducing 10 holdings. Its most notable exit was Allergan plc, an estimated $129M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 61% a quarter earlier, followed by Financials and Industrials.
Against the trend, HealthCor Management opened a new position in Clovis Oncology, Inc. worth $53.4M.
- HealthCor Management's largest Q4 2015 buy was Clovis Oncology, Inc.: 1,525,000 shares worth $53.4M.
- HealthCor Management added most to DexCom in Q4 2015, an estimated $60.3M increase.
- HealthCor Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $113M.
- HealthCor Management fully exited Allergan plc in Q4 2015, selling an estimated $129M.
- HealthCor Management's ten largest holdings make up 56% of its $1.65B portfolio in Q4 2015.
- HealthCor Management opened 19 new positions and closed 22 in Q4 2015.
- HealthCor Management's portfolio value fell 7.3% quarter-over-quarter to $1.65B.
Based on HealthCor Management's 13F filing for Q4 2015, filed 16 Feb 2016.